Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-26-Q-9202

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a solicitation for the establishment of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) in support of the Department of War’s (DoW) integrated pharmacy benefits program for the Military Health System (MHS). This procurement activity is mandated by 10 U.S.C. § 1074g and governed by implementing regulations (32 CFR Section 199.21), which require the DoW to maintain an effective and efficient pharmacy program, including the acquisition of pharmaceutical agents. The primary purpose of this solicitation is to obtain competitive quotations from industry for pharmaceutical agents within specific drug classes identified for potential inclusion in the DoW Uniform Formulary (UF). The UF is a standardized list of medications used across the MHS, and its composition is determined by the DoW Pharmacy and Therapeutics (P&T) Committee based on clinical effectiveness and cost efficiency. The committee also classifies pharmaceutical agents for cost-sharing purposes as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). For the May 2026 P&T Committee meeting, the following drug classes and newly approved drugs will be reviewed: - Cardamyst (Calcium Channel Blocking Agents) - Myqorzo (Cardiovascular Agents Miscellaneous) - Ontralfy (Skeletal Muscle Relaxants and Combinations) - Pivya (Antibiotics - Beta-lactams) - Sdamlo (Calcium Channel Blocking Agents) - Vybrique (Phosphodiesterase-5 Inhibitors - Erectile Dysfunction) - Zycubo (Electrolyte-Mineral-Trace Element Replacement) The scope of this procurement encompasses the submission of quotations for these pharmaceutical agents, with the potential for award of UF BPA and UF ADP agreements based on the UF decision. The solicitation includes detailed instructions, deadlines, and points of contact, all outlined in RFQ HT9402-26-Q-9202 and its appendices. Contractors are expected to respond to clinical questions as specified in Part 3.4 of the RFQ, with submissions directed via email to the designated point of contact by the deadline stated in Part 2.3.2. A pre-quotation teleconference is scheduled for March 11, 2026, with further details provided in Part 2.4 of the RFQ. This session will offer prospective contractors an opportunity to clarify requirements and address any questions prior to submission. Key requirements for this opportunity include: - Demonstrated capability in pharmaceutical preparation manufacturing (NAICS Code 325412, 2022 version) - Experience with the production and supply of the specified drug classes - Compliance with federal regulations and DoW formulary standards - Timely and accurate submission of clinical and pricing information as outlined in the RFQ The place of performance is San Antonio, Texas, and the contracting entity is the Defense Health Agency, a federal office under the Department of Defense. The primary and secondary points of contact for this solicitation are Julianne Canaley ([email protected]) and Tracy Banks ([email protected]), respectively. This solicitation is active, with a response deadline of March 26, 2026, at 18:03. Interested contractors should review the full RFQ and associated attachments available on SAM.gov (Opportunity ID: dd0956db23454b0681616832cd8f5096) for comprehensive instructions and requirements. Contractors evaluating this opportunity should ensure alignment with their manufacturing capabilities, regulatory compliance, and experience in supplying pharmaceutical agents to federal health systems. The requirements and objectives outlined in this solicitation will remain consistent throughout the contract lifecycle, focusing on the provision of clinically effective and cost-efficient pharmaceutical agents for the Military Health System.
Documents10